[{"address1": "12265 El Camino Real", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 727 1040", "fax": "858 614 7007", "website": "https://www.connectbiopharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. Zheng  Wei Ph.D.", "age": 59, "title": "Co-Founder & Director", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wubin  Pan M.B.A., Ph.D.", "age": 58, "title": "Co-Founder & Director", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Barry D. Quart Pharm.D.", "age": 66, "title": "CEO & Director", "yearBorn": 1957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David L. Szekeres", "age": 49, "title": "President", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jiang  Bian J.D.", "title": "General Counsel & Chief Compliance Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lei  Sun Ph.D.", "age": 59, "title": "VP of Biologics & Head of CMC", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raul  Collazo Ph.D.", "title": "VP & Global Head of Medical Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srikanth  Pendyala M.D.", "title": "Senior Vice President of Clinical Development(Consultant)", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.17, "open": 1.22, "dayLow": 1.1502, "dayHigh": 1.2395, "regularMarketPreviousClose": 1.17, "regularMarketOpen": 1.22, "regularMarketDayLow": 1.1502, "regularMarketDayHigh": 1.2395, "beta": -0.346, "forwardPE": -5.8999996, "volume": 26872, "regularMarketVolume": 26872, "averageVolume": 26706, "averageVolume10days": 16380, "averageDailyVolume10Day": 16380, "marketCap": 65199716, "fiftyTwoWeekLow": 0.678, "fiftyTwoWeekHigh": 2.84, "priceToSalesTrailing12Months": 2.7035875, "fiftyDayAverage": 1.25478, "twoHundredDayAverage": 1.36206, "currency": "USD", "enterpriseValue": -44716244, "profitMargins": -0.88655, "floatShares": 14791504, "sharesOutstanding": 55254000, "sharesShort": 45468, "sharesShortPriorMonth": 22411, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0008, "heldPercentInsiders": 0.4116, "heldPercentInstitutions": 0.44486, "shortRatio": 1.75, "shortPercentOfFloat": 0.0015, "impliedSharesOutstanding": 55254000, "bookValue": 1.999, "priceToBook": 0.59029514, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -21380000, "trailingEps": -0.39, "forwardEps": -0.2, "enterpriseToRevenue": -1.854, "enterpriseToEbitda": 1.792, "52WeekChange": -0.26708072, "SandP52WeekChange": 0.31214523, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CNTB", "underlyingSymbol": "CNTB", "shortName": "Connect Biopharma Holdings Limi", "longName": "Connect Biopharma Holdings Limited", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f1aecc10-79bf-31c7-a21a-8af27158e95e", "messageBoardId": "finmb_706016439", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.18, "targetHighPrice": 7.99, "targetLowPrice": 5.99, "targetMeanPrice": 6.99, "targetMedianPrice": 6.99, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 110241000, "totalCashPerShare": 1.995, "ebitda": -24951000, "totalDebt": 325000, "quickRatio": 11.825, "currentRatio": 12.043, "totalRevenue": 24116000, "debtToEquity": 0.294, "revenuePerShare": 0.438, "returnOnAssets": -0.12134, "returnOnEquity": -0.17916, "freeCashflow": -17080772, "operatingCashflow": -24749000, "grossMargins": 1.0, "ebitdaMargins": -1.0346199, "operatingMargins": 0.24639, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-04"}]